Zepbound Maintenance Dose After Goal Weight: What the Evidence Says

Once people reach their goal weight on Zepbound, the natural next question is: what's the maintenance dose? The honest answer surprises a lot of people. There is no separate, lower "maintenance dose" of Zepbound in the way there is for, say, a blood-pressure pill you taper after things stabilize. The FDA label defines three maintenance doses — 5, 10, and 15 mg once weekly — but those are the ongoing treatment doses, not a reduced "you've arrived" setting¹. The best evidence we have says that for most people, the dose that got you to goal is roughly the dose that keeps you there. This page explains why, what the SURMOUNT-4 trial actually showed, and where the popular "drop to the lowest dose that maintains" idea is and isn't supported.

A reminder before the details: Zepbound is the FDA-approved brand of tirzepatide for chronic weight management (Mounjaro is the same molecule approved for type 2 diabetes), it is prescription-only, and every figure below comes from controlled trials of the brand product — not compounded vials, which are not held to the same standards¹.

"Maintenance dose" means something specific on the label

In Zepbound's prescribing information, the word maintenance doesn't mean "the dose you reduce to after losing weight." It means the dose you settle on after finishing the run-in titration. You start at 2.5 mg once weekly for four weeks purely to let the gut adjust — that's not a therapeutic dose — then step up in 2.5 mg increments no closer than four weeks apart. The three doses you can stay on long term are 5, 10, and 15 mg once weekly¹. So when a clinician says "your maintenance dose is 10 mg," they mean the steady weekly dose you continue on, not a special lower setting reserved for after goal weight.

That distinction matters because the term gets read two different ways. The label's meaning is "ongoing dose." The popular meaning is "the smaller dose I switch to once I'm done losing." Those aren't the same thing, and conflating them is where confusion starts.

The key evidence: SURMOUNT-4 and what happens when you stop

The single most important trial for this question is SURMOUNT-4, which was designed specifically to test maintenance. Participants first took tirzepatide for a 36-week lead-in, losing weight as expected. They were then randomized either to continue tirzepatide or to switch to placebo, and were followed to see what happened².

The result was unambiguous. People who continued tirzepatide kept losing or held their loss, while those switched to placebo regained a substantial portion of the weight they'd lost². In other words, the weight loss was not "locked in" by reaching goal — maintaining it depended on staying on the drug. This is the clearest signal we have that there isn't a free ride after goal weight: stopping, or dropping to a non-therapeutic dose, tends to let weight drift back up. We cover the full stopping picture in what happens if you stop tirzepatide.

Why does the weight come back? Tirzepatide reduces appetite and food intake by acting on the GIP and GLP-1 incretin pathways³. While the drug is present at an effective dose, hunger and intake are suppressed. When the drug is withdrawn — or, plausibly, dropped low enough that it's no longer pharmacologically active — those effects fade, appetite returns toward its prior state, and weight tends to regain. Obesity is understood as a chronic, relapsing condition, which is why effective treatment is generally framed as ongoing rather than a finite course.

So is the maintenance dose just "whatever got you to goal"?

For most people, broadly yes. The FDA label frames Zepbound as indicated to reduce excess body weight and maintain that reduction long term, as an adjunct to a reduced-calorie diet and increased physical activity — and that maintenance language assumes continued use of an effective dose, not a step-down to something lower¹. The dose-response data backs this up: in SURMOUNT-1, weight loss rose with dose (about −15% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg over 72 weeks), and there's no trial showing you can bank that loss and then withdraw the dose that produced it⁴. We break the dose-response curve down in what dose of Zepbound is most effective, and the full ladder is laid out in our tirzepatide dosage chart. (If your loss has flattened before reaching goal, that's often normal metabolic adaptation rather than the dose failing — see the tirzepatide weight-loss plateau.)

The cleaner way to think about it: SURMOUNT-4 didn't test "lose on 15 mg, then maintain on 5 mg." It tested "continue your dose" versus "stop." The arm that did well is the one that continued². So the evidence-based default after goal weight is to stay on the effective dose you reached, not to assume a lower number will hold the line.

Where does the "lowest dose that maintains" idea come from?

It's not pulled from nowhere — it's a reasonable clinical instinct, just not a label-defined protocol. The logic runs like this: side effects (mainly gastrointestinal) are dose-dependent, and the gap between 10 mg and 15 mg in average weight loss is small⁴⁵. So if you're at goal and 15 mg is hard to tolerate, a clinician might reasonably try holding at 10 mg, or stepping down, to find the lowest dose that keeps your weight stable — trading a sliver of efficacy for better tolerability. A network meta-analysis of GLP-1-class drugs confirms GI adverse events rise with dose and are worst during increases, which is part of why some people and prescribers favor settling at the lowest workable dose rather than climbing to the maximum⁶.

But two honest caveats apply. First, this is individualized clinical judgment, not a validated protocol — there is no dedicated trial establishing that "lose on a high dose, then maintain on a lower one" reliably holds weight off. SURMOUNT-4 tested continuation versus stopping, not dose-reduction maintenance². Second, off-label tapering schemes you find online are unproven. The idea of stretching the interval between doses, or microdosing to "coast" after goal weight, has no controlled-trial support for maintaining weight, and doing it with compounded product compounds the uncertainty. The label's titration rules set a floor on how fast you go up; they don't endorse any particular step-down maintenance scheme¹.

What this means after you hit your goal weight

Putting it together, here's the evidence-honest framing for the post-goal phase:

• •There's no separate "maintenance dose." The label's maintenance doses are 5, 10, and 15 mg — the ongoing treatment doses, not a reduced after-goal setting¹.
• •Reaching goal doesn't bank the loss. SURMOUNT-4 showed weight returns when treatment stops, so maintenance means continuing an effective dose, not finishing a course².
• •For most people, you stay on the dose that worked. The default is to continue the effective dose, because that's the only approach with direct trial support²¹.
• •A lower maintenance dose is a clinician-individualized trial, not a rule. If tolerability or cost pushes toward a lower dose, your prescriber may try the lowest dose that keeps weight stable — but that's a personalized decision, not a fixed protocol, and it isn't backed by a dedicated maintenance-by-dose-reduction trial⁵⁶.
• •DIY tapering is unproven. Stretching intervals or microdosing to "coast" has no controlled evidence for holding weight, and is riskier with compounded product¹.

Dose also drives cost — a relevant factor in maintenance decisions — and our Zepbound cost and savings guide explains why the higher self-pay vial tiers are priced the same flat rate, which can influence whether a lower dose actually saves money. And because so much hinges on the indication, note that for obstructive sleep apnea — a separate FDA-approved Zepbound use — the evidence and label center on the 10 and 15 mg doses, so "maintenance" sits at the upper end there¹; see Zepbound for sleep apnea.

The honest bottom line

There is no magic "maintenance dose" that locks in your results on a smaller weekly amount. Zepbound's maintenance doses (5, 10, 15 mg) are simply the doses you stay on, and the best trial we have — SURMOUNT-4 — shows that the loss is held by continuing an effective dose, not by reaching goal and easing off². Many people do end up at the lowest dose that keeps them stable, but that's a tolerability-and-cost decision made with a prescriber, individualized to you, not a published protocol — and off-label tapering to "coast" after goal weight has no evidence behind it¹. The realistic mental model is the one the trials and the label both point to: this is a long-term, maintenance therapy, so plan around staying on a dose that works rather than around stopping. For the wider evidence picture, see the tirzepatide evidence guide; to weigh how to access brand Zepbound, start with our best tirzepatide overview.